MedTrace Logo

Interferon-alpha Treatment of Chronic Cough in Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis

NCT00690885 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2012-04-24

No results posted yet for this study

Summary

The purpose of this study is to determine whether lozenges containing interferon-alpha can reduce the frequency and severity of coughing in patients with chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF).

Conditions

Interventions

DRUG

interferon-alpha lozenges

150 IU natural human interferon-alpha lozenges for oral dissolution given 3 times per day for 4 weeks

DRUG

placebo lozenges

matching placebo lozenges

Sponsors & Collaborators

  • Texas Tech University Health Sciences Center

    collaborator OTHER

  • Ainos, Inc. (f/k/a Amarillo Biosciences Inc.

    lead INDUSTRY

Principal Investigators

  • Lorenz O Lutherer, MD, PhD · Texas Tech University Health Sciences Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2012-04-30
Completion
2012-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00690885 on ClinicalTrials.gov